BRAF-话题@MedSci

#BRAF#

112篇内容 | 3434人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1354954, encodeId=def4135495485, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JAMA Oncol：nivolumab对于治疗野生型或突变的BRAF晚期黑色素瘤患者安全且有疗效, objectType=article, longId=53513, objectId=394753513a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=394753513a0, replyNumber=0, likeNumber=53, createdTime=2015-07-20, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=394753513a0, moduleTitle=JAMA Oncol：nivolumab对于治疗野生型或突变的BRAF晚期黑色素瘤患者安全且有疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=394753513a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354953, encodeId=2e7113549533a, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤, objectType=article, longId=51556, objectId=04735155643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04735155643, replyNumber=0, likeNumber=155, createdTime=2015-06-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04735155643, moduleTitle=Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04735155643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354952, encodeId=cd12135495258, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clin Endocrinol：BRAF基因多态性与中国人甲状腺乳头状癌有关, objectType=article, longId=50526, objectId=5f6a5052695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f6a5052695, replyNumber=0, likeNumber=64, createdTime=2015-05-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f6a5052695, moduleTitle=Clin Endocrinol：BRAF基因多态性与中国人甲状腺乳头状癌有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f6a5052695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354951, encodeId=5b671354951c2, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系, objectType=article, longId=49384, objectId=e11b4938401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e11b4938401, replyNumber=0, likeNumber=60, createdTime=2015-04-16, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e11b4938401, moduleTitle=JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e11b4938401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354950, encodeId=8577135495066, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NEJM：Dabrafenib 和Trametinib联合治疗能有效提高恶性黑色素瘤患者的总生存, objectType=article, longId=44919, objectId=ce724491956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce724491956, replyNumber=0, likeNumber=0, createdTime=2015-01-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce724491956, moduleTitle=NEJM：Dabrafenib 和Trametinib联合治疗能有效提高恶性黑色素瘤患者的总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce724491956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354949, encodeId=02aa1354949cd, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NEJM： Dabrafenib与Trametinib联用提高黑色素瘤患者的总生存率, objectType=article, longId=42879, objectId=d0c1428e9ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c1428e9ec, replyNumber=0, likeNumber=69, createdTime=2014-11-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c1428e9ec, moduleTitle=NEJM： Dabrafenib与Trametinib联用提高黑色素瘤患者的总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c1428e9ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet Oncol：威罗非尼改善BRAF突变黑色素瘤患者生存, objectType=article, longId=31709, objectId=877631e09af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=877631e09af, replyNumber=0, likeNumber=73, createdTime=2014-03-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=877631e09af, moduleTitle=Lancet Oncol：威罗非尼改善BRAF突变黑色素瘤患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=877631e09af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354947, encodeId=36ec135494e65, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, objectType=article, longId=24620, objectId=18ab2462050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ab2462050, replyNumber=0, likeNumber=56, createdTime=2013-09-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ab2462050, moduleTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ab2462050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354946, encodeId=d0401354946a0, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JAMA：BRAF基因状态可影响阿司匹林预防结肠直肠癌效果, objectType=article, longId=20830, objectId=6955208300b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6955208300b, replyNumber=0, likeNumber=76, createdTime=2013-07-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6955208300b, moduleTitle=JAMA：BRAF基因状态可影响阿司匹林预防结肠直肠癌效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6955208300b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354945, encodeId=bd8913549457e, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JAMA：BRAF V600E突变与乳头状甲状腺癌显著相关, objectType=article, longId=17478, objectId=104b1e478d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=104b1e478d0, replyNumber=0, likeNumber=77, createdTime=2013-04-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=104b1e478d0, moduleTitle=JAMA：BRAF V600E突变与乳头状甲状腺癌显著相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=104b1e478d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354944, encodeId=5048135494401, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JNCI：PAK1抑制剂能有效治疗BRAF野生型黑色素瘤患者, objectType=article, longId=16984, objectId=17f01698408, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17f01698408, replyNumber=0, likeNumber=0, createdTime=2013-04-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17f01698408, moduleTitle=JNCI：PAK1抑制剂能有效治疗BRAF野生型黑色素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17f01698408)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354943, encodeId=b5a31354943ee, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=PNAS：BRAF基因的突变可能成为儿童脑瘤治疗靶点, objectType=article, longId=16807, objectId=b0241680ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0241680ecf, replyNumber=0, likeNumber=71, createdTime=2013-04-06, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0241680ecf, moduleTitle=PNAS：BRAF基因的突变可能成为儿童脑瘤治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0241680ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354942, encodeId=ada7135494290, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=【ASCO 2012】两大新药治疗BRAF突变黑色素瘤疗效显著, objectType=article, longId=6937, objectId=3636693e14, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3636693e14, replyNumber=0, likeNumber=64, createdTime=2012-06-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3636693e14, moduleTitle=【ASCO 2012】两大新药治疗BRAF突变黑色素瘤疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3636693e14)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354941, encodeId=57d01354941c9, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗, objectType=article, longId=6885, objectId=1fc1688510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fc1688510, replyNumber=0, likeNumber=69, createdTime=2012-06-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fc1688510, moduleTitle=Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fc1688510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354940, encodeId=f5791354940c1, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet：新药dabrafenib或可安全有效地治疗黑色素瘤, objectType=article, longId=6508, objectId=565c6508bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=565c6508bf, replyNumber=0, likeNumber=197, createdTime=2012-05-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=565c6508bf, moduleTitle=Lancet：新药dabrafenib或可安全有效地治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=565c6508bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354939, encodeId=149d1354939ed, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=FDA批准BRAF激酶抑制剂药物CEP-32496的临床试验申请, objectType=article, longId=6474, objectId=ccad64e4ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccad64e4ed, replyNumber=0, likeNumber=66, createdTime=2012-05-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccad64e4ed, moduleTitle=FDA批准BRAF激酶抑制剂药物CEP-32496的临床试验申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccad64e4ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354938, encodeId=846613549389e, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Curr Biol：Ras→BRAF→MEK→ERK细胞信号有助于对黑色素瘤的治疗, objectType=article, longId=6258, objectId=066b625857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=066b625857, replyNumber=0, likeNumber=78, createdTime=2012-05-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=066b625857, moduleTitle=Curr Biol：Ras→BRAF→MEK→ERK细胞信号有助于对黑色素瘤的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=066b625857)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRAF

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#BRAF#

JAMA Oncol：nivolumab对于治疗野生型或突变的BRAF晚期黑色素瘤患者安全且有疗效

2015-07-20

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤

2015-06-04

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clin Endocrinol：BRAF基因多态性与中国人甲状腺乳头状癌有关

2015-05-12

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系

2015-04-16

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NEJM：Dabrafenib 和Trametinib联合治疗能有效提高恶性黑色素瘤患者的总生存

2015-01-03

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NEJM： Dabrafenib与Trametinib联用提高黑色素瘤患者的总生存率

2014-11-21

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet Oncol：威罗非尼改善BRAF突变黑色素瘤患者生存

2014-03-12

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格

2013-09-20

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JAMA：BRAF基因状态可影响阿司匹林预防结肠直肠癌效果

2013-07-05

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JAMA：BRAF V600E突变与乳头状甲状腺癌显著相关

2013-04-18

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JNCI：PAK1抑制剂能有效治疗BRAF野生型黑色素瘤患者

2013-04-11

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

PNAS：BRAF基因的突变可能成为儿童脑瘤治疗靶点

2013-04-06

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

【ASCO 2012】两大新药治疗BRAF突变黑色素瘤疗效显著

2012-06-11

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗

2012-06-09

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet：新药dabrafenib或可安全有效地治疗黑色素瘤

2012-05-26

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

FDA批准BRAF激酶抑制剂药物CEP-32496的临床试验申请

2012-05-26

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Curr Biol：Ras→BRAF→MEK→ERK细胞信号有助于对黑色素瘤的治疗

2012-05-21

科室
- - 订阅+
  - 更多科室
工具
服务